YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Illumina Offered the Counter Bid for Complete Genomics


November 18, 2012 | As suspected by many, Illumina says it was the second bidder for Complete Genomics. Complete rejected Illumina's offer--a 5% premium over the BGI offer--because the deal would have likely been stalled by antitrust regulators. Illumina says the offer was in cash. Bloomberg
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.